ReviewMedComm2020
Engineered biomaterials for cancer immunotherapy.
Review in MedComm, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Modular noncovalent functionalization of electrospun piezoelectric scaffolds with bioactive nanocarriers.Biomaterials science · 2026Article
- The multiplex crosstalk between non-coding RNAs, programmed cell death and related mechanisms: a dynamic duo in hematological malignancies.Cancer cell international · 2025Review
- Immune-based cancer therapies: mechanistic insights, clinical progress, and future directions.Journal of the Egyptian National Cancer Institute · 2025Review
- Comprehensive insights into glioblastoma multiforme: drug delivery challenges and multimodal treatment strategies.Therapeutic delivery · 2025Review
- Immune Cell Homing Hydrogels for Cancer Immunotherapy.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Research Progress on the Application of Natural Medicines in Biomaterial Coatings.Materials (Basel, Switzerland) · 2024Review
- Overcoming neutrophil-induced immunosuppression in postoperative cancer therapy: Combined sialic acid-modified liposomes with scaffold-based vaccines.Asian journal of pharmaceutical sciences · 2024Article
- Extracellular Matrix Scaffold-Assisted Tumor Vaccines Induce Tumor Regression and Long-Term Immune Memory.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- Biomaterial-Based Responsive Nanomedicines for Targeting Solid Tumor Microenvironments.Pharmaceutics · 2024Review
- Cellular-Membrane-Derived Vesicles for Cancer Immunotherapy.Pharmaceutics · 2023Review
- Review
- Bio-adhesive Macroporous Hydrogels for In Situ Recruitment and Modulation of Dendritic Cells.Cellular and molecular bioengineering · 2023Article
- Tumor microenvironment-responsive spherical nucleic acid nanoparticles for enhanced chemo-immunotherapy.Journal of nanobiotechnology · 2023Article
- Emerging biomaterials for tumor immunotherapy.Biomaterials research · 2023Review
- A self-charging salt water battery for antitumor therapy.Science advances · 2023Article
- Microneedles for Efficient and Precise Drug Delivery in Cancer Therapy.Pharmaceutics · 2023Review
- Recent Advances in Cancer Immunotherapy Delivery Modalities.Pharmaceutics · 2023Review
- URB2 as an important marker for glioma prognosis and immunotherapy.Frontiers in pharmacology · 2023Article
- Locoregional Lymphatic Delivery Systems Using Nanoparticles and Hydrogels for Anticancer Immunotherapy.Pharmaceutics · 2022Review
- Engineering Surfaces with Immune Modulating Properties of Mucin Hydrogels.ACS applied materials & interfaces · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although cancer immunotherapy is showing tremendous promise and has progressed to the clinic, it has only achieved sporadic efficacy, with only a fraction of patients benefitting from the therapy and with undesirable side effects due to poor selectivity and high doses. Localized delivery of immunomodulators to activate anticancer immunity in situ avoids overactivation of the systemic immune system and reduces side effects. Engineered biomaterials-implantable, injectable, or transdermal-fabricated into drug delivery devices are critical components for the development of localized cancer immunotherapies. In this review, we briefly summarize progress in the application of engineered biomaterials to the localized delivery of cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.